[Changes and challenges of surgical treatment strategy for hepatocellular carcinoma].
Zhonghua Wai Ke Za Zhi
; 59(6): 447-451, 2021 Jun 01.
Article
en Zh
| MEDLINE
| ID: mdl-34102726
ABSTRACT
Hepatocellular carcinoma(HCC) is a common malignant tumor with high morbidity and mortality in China and even in the world.Due to its tumor heterogeneity and dissemination and distant metastasis,prognosis of patients with HCC is often poor.Surgical treatment such as radical hepatectomy is still the first choice for patients with HCC in the current clinical practice.However,the high recurrence and metastasis rate after surgery still hinder the survival and prognosis of these patients.In the era of target and immunotherapy,changes of surgical treatment strategy for HCC is particularly critical.This review focuses on the definition,the feasibility and the evaluation criteria of neoadjuvant therapy for HCC,to provide a new perspective on surgical treatment for HCC.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Neoplasias Hepáticas
Tipo de estudio:
Prognostic_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Zhonghua Wai Ke Za Zhi
Año:
2021
Tipo del documento:
Article
País de afiliación:
China